Cite
APA Citation
Kosmas, I. P., Kitsou, C., Lazaros, L., Markoula, S., Peschos, D., Mynbaev, O., Tournaye, H., Prapas, N., Prapas, I., Zikopoulos, A., Galani, V., & Georgiou, I. (n.d.). everolimus, an mTOR pathway inhibitor, is highly successful on ovarian hyperstimulation syndrome by reducing ovarian weight and progesterone levels: a preclinical experimental randomized controlled study. Gynecological endocrinology, 31, 702–707. http://access.bl.uk/ark:/81055/vdc_100089569308.0x00003d